Article Text

Download PDFPDF
Congenital rubella syndrome: the end is in sight
  1. Scott R Lambert
  1. Scott R Lambert, Emory Eye Center, 1365-B Clifton Road, NE, Atlanta, GA 30322, USA; slamber{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rubella vaccination programmes offer hope in eradicating congenital rubella syndrome in developing countries

Rubella is usually a mild febrile illness associated with a rash, lymphadenopathy, conjunctivitis, malaise and arthralgia. In 1941, an Australian ophthalmologist, Norman Gregg, first reported the association between congenital cataracts and a rubella infection during pregnancy in an article entitled “Congenital cataract following German measles in the mother”.1 This condition is now referred to as congenital rubella syndrome (CRS). It occurs as a result of a maternal rubella infection during the first trimester of pregnancy when organogenesis is occurring and is most commonly associated with hearing impairment (60%), congenital heart disease (45%), microcephaly (27%) congenital cataracts (25%) and mental retardation (13%). During the early 1960s, there was a worldwide pandemic of CRS. In the United States alone, 20 000 children were born with CRS between 1962 and 1965. In 1969, a live attenuated rubella vaccine was licensed in the US, and widespread vaccination of children was initiated. As a result, CRS has almost been eradicated from the US. Between 2001 and 2004, there were only 4 reported cases of CRS in the US, of which 3 were …

View Full Text


  • Supported in part by NIH Departmental Core Grant EY06360 and Research to Prevent Blindness, Inc.

  • Abbreviation:

    congenital rubella syndrome

Linked Articles